Cytokinetics Announces Presentations Relating to Tirasemtiv at the 25th International Symposium on ALS/MND

South San Francisco, CA, December 1, 2014 - Cytokinetics, (Nasdaq: CYTK) announced today that presentations relating to tirasemtiv are scheduled during  the 25th International Symposium on ALS/MND to be held December 5-7, 2014 at the Square Brussels Meeting Centre in Brussels, Belgium.  Tirasemtiv is the lead drug candidate from Cytokinetics' skeletal muscle contractility program. Tirasemtiv selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium and, in preclinical studies and early clinical trials, demonstrated increases in skeletal muscle force in response to neuronal input and delays in the onset and reductions in the degree of muscle fatigue.  Tirasemtiv was the subject of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv ALS), a Phase IIb, multi-national, double-blind, randomized, placebo-controlled, clinical trial designed to evaluate the safety, tolerability and efficacy of tirasemtiv in patients with ALS.

Oral Presentation at the 25th International Symposium on ALS/MND

Date:   Friday, December 5, 2014
Location:  Square Brussels Meeting Centre, Copper Hall
Presentation Time:  2:40 PM-3:00 PM (Central European Time)
Session:  3B - Trials and Trial Design
Title:  The Effects of Tirasemtiv on Measures of Respiratory Function in Amyotrophic Lateral Sclerosis
Presenter:  Jinsy Andrews, MD, MSc, Director, Clinical Research and Development, Cytokinetics

Poster Presentations at the 25th International Symposium on ALS/MND

Date:  Friday, December 5, 2014
Location:  Square Brussels Meeting Centre, Grand Hall 1
Presentation Time: 5:30 PM - 7:30 PM
Session: Poster Session A
Theme:  6 - Epidemiology
Poster Number:  P133
Title:  Profile of Medical Care Costs in Patients with Amyotrophic Lateral Sclerosis in Medicare Program and Under Commercial Insurance
Presenter:  Lisa Meng, PhD, Director, Biometrics, Cytokinetics
Poster Moderated:  6:00 PM - 6:30 PM (Central European Time)

Date:  Saturday, December 6, 2014
Location:  Square Brussels Meeting Centre, Grand Hall 1
Presentation Time: 5:30 PM - 7:30 PM
Session: Poster Session B
Theme:  4 - Respiratory and Nutritional Management
Poster Number:  P82
Title:  Effect of Tirasemtiv on Submaximal Rodent Diaphragm Strength and Respiratory Function
Presenter:  Darren Hwee, PhD, Scientist, Cytokinetics
Poster Moderated:  5:45 PM - 6:20 PM (Central European Time)

Date:  Saturday, December 6, 2014
Location:  Square Brussels Meeting Centre, Grand Hall 1
Presentation Time: 5:30 PM - 7:30 PM
Session: Poster Session B
Theme:  11 - Therapeutic Strategies
Poster Number:  P283
Title:  Relationships Between Riluzole and Tirasemtiv Levels on Outcomes in the BENEFIT-ALS Trial
Presenter:  Jeremy Shefner, MD, PhD, Professor & Chair of Neurology, Barrow Neurological Institute
Poster Moderated:  6:20 PM - 6:55 PM (Central European Time)

Date:  Saturday, December 6, 2014
Location:  Square Brussels Meeting Centre, Grand Hall 1
Presentation Time: 5:30 PM - 7:30 PM
Session: Poster Session B
Theme:  11 - Therapeutic Strategies
Poster Number:  P286
Title:  Fast Skeletal Muscle Troponin Activator Tirasemtiv Increases Muscle Function and Performance in Mouse Models of Spinal Muscular Atrophy
Presenter:  Darren Hwee, PhD, Scientist, Cytokinetics
Poster Moderated:  6:20 PM - 6:55 PM (Central European Time)

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.  Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure.  Amgen Inc. holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights.  Cytokinetics is independently developing tirasemtiv, a fast skeletal muscle activator, as a potential treatment for diseases and medical conditions associated with neuromuscular dysfunction.  Tirasemtiv is the subject of a Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis (ALS).  Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a skeletal muscle activator structurally distinct from tirasemtiv, for non-neuromuscular indications.  All of these drug candidates have arisen from Cytokinetics' muscle biology focused research activities and are directed towards the cytoskeleton.  The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell.  Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' research and development activities, including the potential significance and utility of the results from preclinical studies and clinical trials of tirasemtiv; planned further analyses of the results from BENEFIT-ALS and the potential outcomes of such analyses; potential further development of tirasemtiv; planned presentations; and the properties and potential benefits of skeletal muscle activators and of tirasemtiv and Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Contact:
Joanna L. Goldstein
Manager, Investor Relations & Corporate Communications
(650) 624-3000